生物制药公司Hoth Therapeutics近日透露,其针对特应性皮炎的新型疗法已向西班牙与波兰监管机构提交审批申请,预计短期内将获得通过。这意味着该公司位于两国的临床试验站点有望迅速投入运营,加速推进其创新药物的国际化布局。
生物制药公司Hoth Therapeutics近日透露,其针对特应性皮炎的新型疗法已向西班牙与波兰监管机构提交审批申请,预计短期内将获得通过。这意味着该公司位于两国的临床试验站点有望迅速投入运营,加速推进其创新药物的国际化布局。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.